» Articles » PMID: 35070954

CXCR4 Mediates Enhanced Cell Migration in Leukemia

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Jan 24
PMID 35070954
Authors
Affiliations
Soon will be listed here.
Abstract

Leukemia transformed by the chromosomal translocation is characterized by a high incidence of extramedullary disease, central nervous system (CNS) relapse, and a poor prognosis. Invasion of the extramedullary compartment and CNS requires leukemia cell migration out of the marrow and adherence to the cells of the local tissue. Cell adhesion and migration are increasingly recognized as contributors to leukemia development and therapeutic response. These processes are mediated by a variety of cytokines, chemokines, and their receptors, forming networks of both secreted and cell surface factors. The cytokines and cytokine receptors that play key roles in driven leukemia are unknown. We find high cell surface expression of the cytokine receptor CXCR4 on leukemia cells expressing the CALM-AF10 oncogenic protein, contributing to the migratory nature of this leukemia. Our discovery of altered cytokine receptor expression and function provides valuable insight into the propagation and persistence of driven leukemia.

Citing Articles

Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.

Spertini C, Benechet A, Birch F, Bellotti A, Roman-Trufero M, Arber C Cell Death Discov. 2024; 10(1):157.

PMID: 38548753 PMC: 10978870. DOI: 10.1038/s41420-024-01924-5.


Current methods for studying metastatic potential of tumor cells.

Bouchalova P, Bouchal P Cancer Cell Int. 2022; 22(1):394.

PMID: 36494720 PMC: 9733110. DOI: 10.1186/s12935-022-02801-w.

References
1.
Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink F . High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001; 115(3):545-53. DOI: 10.1046/j.1365-2141.2001.03164.x. View

2.
Wang S, Wang X, Liu S, Zhang S, Wei X, Song Y . The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia. Onco Targets Ther. 2020; 13:6583-6591. PMC: 7352451. DOI: 10.2147/OTT.S249425. View

3.
Cooper T, Sison E, Baker S, Li L, Ahmed A, Trippett T . A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics.... Pediatr Blood Cancer. 2017; 64(8). PMC: 5675008. DOI: 10.1002/pbc.26414. View

4.
Sison E, Mcintyre E, Magoon D, Brown P . Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013; 11(9):1004-16. PMC: 3778118. DOI: 10.1158/1541-7786.MCR-13-0114. View

5.
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha U, Pitsillides C . Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2006; 109(7):2708-17. PMC: 1852222. DOI: 10.1182/blood-2006-07-035857. View